Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
5.05
-0.06 (-1.17%)
Oct 6, 2026, 9:52 AM EDT - Market open
Abeona Therapeutics Revenue
Abeona Therapeutics had revenue of $11.38M in the quarter ending June 30, 2026, with 2,745.00% growth. This brings the company's revenue in the last twelve months to $25.52M. In the year 2025, Abeona Therapeutics had annual revenue of $5.82M.
Revenue (ttm)
$25.52M
Revenue Growth
+6,280.00%
P/S Ratio
11.45
Revenue / Employee
$112,920
Employees
226
Market Cap
288.78M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.82M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 3.50M | 2.09M | 147.52% |
| Dec 31, 2022 | 1.41M | -1.59M | -52.87% |
| Dec 31, 2021 | 3.00M | -7.00M | -70.00% |
| Dec 31, 2020 | 10.00M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 3.00M | 2.16M | 258.18% |
| Dec 31, 2017 | 837.00K | -52.00K | -5.85% |
| Dec 31, 2016 | 889.00K | -151.00K | -14.52% |
| Dec 31, 2015 | 1.04M | 115.00K | 12.43% |
| Dec 31, 2014 | 925.00K | -1.12M | -54.70% |
| Dec 31, 2013 | 2.04M | -2.36M | -53.63% |
| Dec 31, 2012 | 4.40M | 2.57M | 139.48% |
| Dec 31, 2011 | 1.84M | 1.36M | 282.33% |
| Dec 31, 2010 | 481.00K | 129.00K | 36.65% |
| Dec 31, 2009 | 352.00K | 61.00K | 20.96% |
| Dec 31, 2008 | 291.00K | 234.00K | 410.53% |
| Dec 31, 2007 | 57.00K | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 215.72M |
| Century Therapeutics | 109.16M |
| Fulcrum Therapeutics | 80.00M |
| Clinuvel Pharmaceuticals | 65.05M |
| X4 Pharmaceuticals | 15.85M |
| Fate Therapeutics | 6.49M |
| Upstream Bio | 3.16M |
| EyePoint | 2.79M |
ABEO News
- 4 days ago - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 18 days ago - Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111 - TheFly
- 18 days ago - Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA) - GlobeNewsWire
- 18 days ago - Abeona Therapeutics price target raised to $30 from $28 at Cantor Fitzgerald - TheFly
- 19 days ago - Abeona Therapeutics initiated with a Buy at Roth Capital - TheFly
- 19 days ago - Abeona Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 20 days ago - Abeona activates UF Health as qualified treatment center for Zevaskyn - TheFly
- 20 days ago - Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN® - GlobeNewsWire